eGastroenterology review weighs semaglutide's role in MASH cirrhosis
Zhou, Alkhouri, Schattenberg and colleagues ask whether the GLP-1 agonist represents a genuine option in compensated cirrhosis from metabolic liver disease.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 24 20:00 ETSource: eGastroenterology
The wire
- 01The journal published a review article assessing semaglutide as a therapeutic candidate in MASH-related cirrhosis, framed in its title as either a new frontier or a false dawn.
- 02MASH cirrhosis has few approved drug options, so clinicians are watching whether incretin therapy extends beyond earlier fibrosis stages.
- 03This is a review and commentary rather than new trial data; readers should look to the underlying randomized evidence it discusses.
From the source
Read at pubmed.ncbi.nlm.nih.govSemaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?
eGastroenterology · 2026 · Zhou XD, Alkhouri N, Schattenberg JM et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42825265/
